Introduction {#Sec1}
============

The novel 2019 coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) results in a variety of symptoms including fever, cough, and fatigue \[[@CR1]\]. As more is learned, it has become apparent that neurologic involvement in COVID-19 may be important in some patients. A subset of patients presents with neurologic symptoms such as headache, dizziness, or a cerebrovascular event \[[@CR2]\]. Reports have also implicated isolated, sudden onset of anosmia and ageusia as early indicators of SARS-CoV-2 infection, suggesting that early neurological involvement may be relevant \[[@CR3]\]. Of great concern are the potential long-term neurologic complications from COVID-19 infection. Here, we synthesize the literature to highlight clinical observations that suggest important associations between SARS-CoV-2 infection and the nervous system and discuss potential mechanisms of neural injury. Awareness of the possible neurological manifestations in COVID-19 patients is of utmost importance to assist providers in the recognition, treatment, and management of potentially life-threatening neurologic complications.

Clinical Observations {#Sec2}
=====================

While SARS-CoV-2 presents primarily as a respiratory disease, injury to other organ systems, including the nervous system, is well documented \[[@CR4]\]. These observations shed light on the broad physiological impact of COVID-19, and awareness of these extrapulmonary features may help inform the overall prognosis in patients affected. The reported neurologic effects of COVID-19 infection are myriad and may include complications related to viral infection, immune response, critical illness, related therapies and recovery. A retrospective study of 214 COVID-19 patients from Wuhan, China, found that 36.4% of patients had neurologic manifestations of the disease, including symptoms relating to the central nervous system (24.8%), peripheral nervous system (8.9%) and skeletal muscle injury (10.7%). The most common neurologic manifestations were dizziness (16.8%) and headache (13.1%). Severely ill patients were more likely than less severely afflicted patients to exhibit neurologic symptoms (45.5% vs. 30.2%, respectively) including cerebrovascular disease (seen in 5.7% and 0.8%, respectively), impaired consciousness (14.8% vs. 2.4%), and skeletal muscle injury (19.3% vs. 4.8%) \[[@CR4]\].

A recently published report of 58 patients admitted to two intensive care units in Strasbourg, France, with COVID-19-associated-ARDS found neurological features associated with the illness in 14% of the patients on admission to the ICU, in 67% when sedation was lifted, and overall in 84% when considering all neurological complications through hospital discharge. Neurologic symptoms cataloged in this study included agitation (69%), confusion (65%), and corticospinal tract signs (67%). Notably, 33% of the patients discharged from the hospital were found to have an executive dysfunction syndrome such as inattention, disorientation or poorly organized movements. MRI was performed in 13 of 64 patients for encephalopathic features. Among these, bilateral frontotemporal hypoperfusion abnormalities were seen in 11/11 (100%), acute or subacute stroke in 3/13 (23%) and enhancement of leptomeningeal spaces in 8/13 (62%). Eight patients underwent electroencephalography. One demonstrated a pattern of diffuse bilateral slowing while others had non-specific findings. CSF samples were obtained from 7 patients; two patients had oligoclonal bands, one had elevated protein and IgG levels and no patients had PCR assays positive for SARS-CoV-2 \[[@CR5]\]. In another multi-center, retrospective cohort, 50 of 235 ICU patients were found to have neurologic symptoms (21%) \[[@CR6]\]. Twenty-seven of these underwent MRI, and acute imaging abnormalities were found in 44% (12/27) including, most commonly, cortical fluid-attenuated inversion recovery (FLAIR) signal abnormalities in non-specific distributions affecting the frontal, temporal, parietal, occipital, cingulate or insular cortex, as might be seen with infectious or autoimmune encephalitis, a post-ictal state, hypoxia or hypoglycemia. Subcortical and deep white matter signal changes accompanied these findings (6/10), and leptomeningeal enhancement (5/8 patients) was also seen. In addition, one patient presented with a large-vessel AIS and another with CVST. CSF testing demonstrated elevated protein in 6 out of 7 patients tested; all had normal cell counts and 2 had negative PCR assays for SARS-CoV-2 \[[@CR6]\].

Though case reports of possible encephalitis associated with COVID-19 are reported \[[@CR7], [@CR8]\], we found one isolated report of SARS-CoV-2 being detected in the CSF of symptomatic patients. SARS-CoV-2 RNA was detected in the CSF by RT-PCR, but not the nasal swab, of a 24-year-old man in Japan \[[@CR9]\]. This patient had clinical findings of encephalitis, including seizure, headache, stiff neck, elevated CSF pressure, and a WBC count of 12/μL \[[@CR9]\]. Magnetic resonance imaging (MRI) with diffusion weighted imaging (DWI) demonstrated hyperintensity along the inferior horn of the right lateral ventricle, FLAIR sequences showed hyperintense signal changes in the right mesial temporal lobe with hippocampal atrophy, and T2-weighted imaging revealed paranasal sinusitis \[[@CR9]\]. This patient was diagnosed with encephalitis associated with SARS-CoV-2 \[[@CR9]\]. In contrast, Doung et al. describe a patient with headache and fever who presented with new seizure in the absence of respiratory symptoms. CSF was not tested for SARS-CoV-2, but additional tests did suggest an aseptic meningitis with an elevated WBC count and lymphocytic predominance. A nasopharyngeal swab confirmed COVID-19 infection \[[@CR7]\]. In another case, a patient admitted with COVID-19 developed signs of meningeal irritation and alteration in consciousness. A head CT and lumbar puncture were normal. Bacterial and viral CSF studies were negative including SARS-CoV-2 PCR testing, but the patient was diagnosed with COVID-19-associated meningoencephalitis with the authors postulating transient dissemination of the virus in the CSF with a robust inflammatory response \[[@CR10]\].

Interestingly, postmortem examination of a patient infected with SARS-CoV-2, who presented with confusion and mental status changes, detected virus in frontal lobe neurons by electron microscopy despite negative CSF PCR testing. Viral particles were also identified in brain capillary endothelial cell and seen actively budding from endothelial cells, both providing the first direct evidence of SARS-CoV-2 in human brain tissue and implicating a potential direct hematogenous route for CNS seeding \[[@CR11]\]. This report has been followed by a second, identifying and quantifying SARS-CoV-2 virus in brain tissue samples from 8 of 22 patients (36%) who died from COVID-19 infection \[[@CR12]\], more firmly establishing COVID-19's neurotropic potential.

Another case describes a COVID-19 patient with cough, fever, and altered mental status who was diagnosed with acute necrotizing encephalopathy (ANE) \[[@CR8]\]. A non-contrast CT demonstrated symmetric hypoattenuation within the bilateral medial thalami with normal CT angiogram and venogram. MRI showed characteristic hemorrhagic rim enhancing lesions within the thalami, medial temporal lobes, and subinsular regions \[[@CR8]\]. ANE is a rare but well-recognized complication of viral illnesses, particularly in children \[[@CR13], [@CR14]\] and was reported in adults during the novel influenza A H1N1 pandemic \[[@CR15]\]. Although the pathogenesis of ANE is not known, it is hypothesized to be immune-mediated, with more than 90% of cases preceded by fever and upper respiratory infection. Elevated CSF and serum cytokines have been linked to the disease presentation in both adults and children, and some authors have suggested hyper-cytokinesis may play a role in driving endothelial damage and blood--brain barrier disruption \[[@CR16]--[@CR18]\]. Whether SARS-CoV-2 may cause acute viral meningitis-encephalitis or viral associated encephalopathy syndromes, as have been associated with other viral illnesses, remains to be elucidated.

Acute demyelinating polyneuropathy associated with SARS-CoV-2 infection has also been described \[[@CR19]\]. A case series from Italy reports 5 patients who developed Guillain--Barre Syndrome (GBS) between 5 and 10 days after the onset of typically described COVID-19 symptoms, including fever, cough, anosmia and ageusia \[[@CR20]\], a similar time-interval to the development of GBS observed in other viral illnesses. SARS-CoV-2 RT-PCR of the CSF was negative in all 5 of these patients \[[@CR21]\]. A case of a patient who developed the typical progressive weakness of the distal lower extremities evolving to quadriplegia approximately 2 weeks after acute COVID-19 infection is reported separately \[[@CR22]\], as is a series of two patients who developed Miller Fisher variant and polyneuritis cranialis, respectively, notably in the time-course of acute COVID-19 infection \[[@CR23]\]. In China, a 61-year-old otherwise asymptomatic woman presented with acute symmetric weakness and areflexia in the lower extremities. This patient was also diagnosed with GBS; 8 days later she developed typical COVID-19 symptoms and SARS-CoV-2 infection was confirmed. At the time of hospital discharge, both respiratory and neurological symptoms had resolved \[[@CR19]\]. Because relatively little is yet known about SARS-CoV-2, profound muscle weakness and difficulty weaning off the ventilator are well described, and there is significant clinical overlap between critical illness neuropathy-myopathy and the symptoms of GBS, it may be important to consider this atypical complication of viral infection in critically ill patients.

There is now a well-documented association of anosmia and ageusia with COVID-19. Although olfactory dysfunction can commonly occur with viral illness second to mucosal inflammation, what appears to be unique to COVID-19 may be the development of anosmia and hyposmia in the absence of nasal obstruction or rhinorrhea. A study that included 417 patients with mild-to-moderate COVID-19 infection admitted to 12 European hospitals found that 85.6% and 88.0% of patients reported anosmia and ageusia, respectively \[[@CR3]\]. The concurrent appearance of both symptoms was statistically significant (*p* \< 0.001), though either anosmia or ageusia can also occur alone. Olfactory dysfunction manifested before any classical upper respiratory or pulmonary symptoms in 11.8% of cases \[[@CR3]\]. While 18.2% of patients denied rhinorrhea symptoms, nearly 80% of these patients reported reduced olfaction or complete anosmia \[[@CR3]\]. A cross-sectional study that included 59 patients with severe COVID-19 hospitalized in Italy found 33.9% reported anosmia or ageusia \[[@CR24]\]. Loss of smell was threefold higher in subjects who tested positive for SARS-CoV-2 (59%) than in subjects who tested negative (18%) in a population-based study in the UK \[[@CR25]\], and ten-fold higher among ambulatory clinic patients in the USA who tested positive for COVID-19 \[[@CR26]\]. The etiology of this phenomenon, and whether it is limited to injury or inflammation in epithelial tissue or represents a possible route of retrograde axonal transport to the CNS is an area of investigation. For example, yet-to-be peer-reviewed reports of bulk sequencing gene expression studies have suggested that, as with the respiratory epithelium, the human olfactory epithelium expresses both ACE2 and TMPRSS2, key genes thought to be involved in SARS-CoV-2 infection \[[@CR27], [@CR28]\]. However, by using single cell RNA-sequencing analysis and immunostaining techniques, expression of ACE2 was isolated, not to olfactory sensory neurons or neurons of the olfactory bulb, but to the non-neuronal support cells of the olfactory epithelium, and sustentacular cells in particular \[[@CR28]\]. This suggests that non-neuronal epithelial tissue may be the infectious target.

A clinical report describes a SARS-CoV-2 patient with mild respiratory symptoms and acute anosmia in which bilateral hyperintensity of the olfactory bulbs and of the right gyrus rectus on FLAIR sequence was seen on an MRI performed on day 4 of symptoms \[[@CR29]\]. Follow-up imaging 28 days later showed resolution of cortical hyperintensities with slight reduction in thickness of the olfactory bulbs, though clinically the patient had recovered. Notably, two other clinically similar patients had MRI with FLAIR performed on days of illness 12 and 25 that were completely unremarkable. This case, therefore, represents an intriguing and unique report---possibly an in vivo snapshot of viral involvement in an area of the brain associated with olfaction, and it points to what may be one pathway of viral infection from olfactory mucosa to the brain.

Recent studies have shed light on vascular-thrombotic complications associated with COVID-19 infection \[[@CR1], [@CR30], [@CR31]\]. Coagulation abnormalities are common in severe illness and appear to be an important indicator of poor prognosis \[[@CR31]\]. Sepsis-induced coagulopathy (SIC) has been described in 21.6% of patients classified with severe COVID-19 and associated with mortality. Heparin treatment in those with SIC or with a markedly elevated d-dimer was also associated with improved survival \[[@CR31], [@CR32]\]. The incidence of arterial or venous thromboembolism has been reported to be between 8 and 31% in patients hospitalized with COVID-19, despite treatment with prophylactic anticoagulation, including deep venous thromboembolism (VTE), pulmonary embolism, acute ischemic stroke (AIS), and cerebral venous sinus thrombosis \[[@CR33]--[@CR35]\]. One center noted that the rate of VTE in COVID-19 infected patients was more than five times greater than that of comparable historical control groups such as patients admitted with non-COVID ARDS or influenza \[[@CR36]\]. The American Society of Hematology has recommended that hospitalized patients with COVID-19 be treated with standard thromboprophylaxis \[[@CR37]\], but there remains intense debate about the possible benefit of intensified anticoagulation regimens \[[@CR38]\].

AIS has been reported in 2.3--5% of patients hospitalized with COVID-19 \[[@CR4], [@CR5], [@CR39]\], though patient series and case reports of AIS continue to accumulate \[[@CR40]--[@CR42]\]. Three COVID-19 patients with multi-vessel AIS and positive antiphospholipid antibodies are described in a recent case series. A 69-year-old patient with no significant past medical history was found to have multiple bilateral cerebral infarcts and bilateral jugular venous thrombi. In the same series, another 69-year-old patient developed ischemia in both lower limbs and two digits of his left hand and had bilateral cerebral infarcts in multiple vascular territories as revealed by CT imaging \[[@CR40]\]. In these patients, anti-cardiolipin and anti-B2-glycoprotein antibodies were positive and lupus anticoagulant (LAC) was negative. In a prospective French series of COVID-19 patients, anti-cardiolipin antibodies were found in 10% and LAC in 45% of a hospitalized cohort \[[@CR43]\]. A retrospective study of 221 hospitalized COVID-19 patients found cerebrovascular disease in a significant minority with 5% of the patients developing acute ischemic stroke, 0.5% cerebral venous sinus thrombosis, and 0.5% cerebral hemorrhage \[[@CR39]\]. Patients with cerebrovascular disease had a heightened inflammatory response and abnormal coagulation with elevated C-reactive protein (CRP) and d-dimer levels. In this series, older age was a risk factor (mean age 71.6 years in the group with cerebrovascular disease versus 52.1 years in those without; *p* \< 0.05) \[[@CR39]\]. However, AIS has also been described in young patients \[[@CR42]\] and even as a presenting feature of COVID-19. A case series from New York described five SARS-CoV-2-positive patients under the age of 50 who presented to medical attention with large-vessel strokes. Only one of the patients in this notable series had a previous history of stroke \[[@CR41]\].

There is mounting evidence to suggest that the vascular endothelium may be a key organ in COVID-19 infection. Clinically, it has been noted that the most frequent comorbidities of patients hospitalized with SARS-CoV-2 infection are hypertension, diabetes, and cardiovascular disease, which share endothelial dysfunction as a common feature \[[@CR44]\]. The endothelium is also a principal regulator of thrombosis and hemostasis, and endothelial cell dysfunction, induced by COVID-19 infection, may be an important driver of coagulopathy and increased thrombotic burden. Endothelial cell activation induced by infection and resultant disruption of the antithrombotic endothelial surface, excess thrombin generation, and early termination of fibrinolysis are possible contributors to the thrombotic state \[[@CR45]\]. Because vascular endothelial cells express ACE2 receptors in abundance, in addition to many other of the cell surface receptors used by SARS-CoV-2 for cell entry, direct viral infection of vascular endothelial cells has also been posited \[[@CR38], [@CR44], [@CR45]\]. Varga et al. demonstrated endothelial viral invasion by SARS-CoV-2 on pathology specimens affecting blood vessels in the heart, kidneys, lungs, and small intestine \[[@CR46]\]. Virus in the endothelium was accompanied by inflammatory cells and evidence of endothelial cell death, suggestive of an endotheliitis, which might explain microcirculatory injury or failure exacerbating critical illness and organ injury. An interesting clinical case report describes a severely ill patient with COVID-19, ARDS, acute renal failure, and altered mental status in whom von Willebrand factor, a marker of endothelial stimulation and damage, was massively elevated at 500% of normal \[[@CR47]\]. The Kawasaki-like syndrome that is now described in young patients following COVID-19 infection and associated with a hyper-inflammatory state is further suggestive of a vascular inflammatory potential of SARS-CoV-2 \[[@CR48], [@CR49]\].

The longer-term complications of COVID-19 infection remain unknown. As the virus proliferates in lung tissue, inducing inflammation and edema, alveolar gas exchange is disrupted, with the potential to cause hypoxia, anaerobic metabolism, and acid accumulation \[[@CR50]\]. Acidosis risks increasing cerebral vasodilation and promoting cerebral edema \[[@CR50]\]. Some concern may be raised by autopsy findings of patients infected with other coronaviruses. Autopsies of 8 confirmed SARS-CoV cases in China revealed cerebral edema and marked neuronal injury \[[@CR51]\]. Recently, brain autopsies of 18 patients who tested positive for SARS-CoV-2 revealed hypoxic changes in the cerebellum and cerebrum, with neuronal loss in the cerebral cortex, hippocampus, and cerebellar Purkinje cell layer \[[@CR52]\]. These studies suggest that CNS injury secondary to severe pulmonary dysfunction may occur. The degree and extent of CNS injury in earlier phases of the disease process, and to what extent this may be clinically relevant to SARS-CoV-2, are still unclear. The clinical observations that have been reported in COVID-19 shed light on the many potential adverse effects of SARS-CoV-2 infection on the nervous system and, in particular, how any specific effects of the virus might overlay on commonly observed consequences of critical illness such as critical illness encephalopathy, critical illness neuropathy, and critical illness myopathy. Subsequent studies must address both the short and important long-term neurological consequences of COVID-19 infection and how we can best mitigate disability and avoid morbidities.

Potential Mechanisms of SARS-CoV-2 Mediated Neurological Injury {#Sec3}
===============================================================

The known pathophysiology of SARS-CoV-2 and the other Human Coronaviruses offer clues regarding possible mechanisms of neurological damage. SARS-CoV-2 has now been shown to be capable of invading the CNS, as have other Human Coronaviruses (HCoV), the viral group of which SARS-CoV-2 is a member. SARS-CoV-2 invasion is thought to require both a cell surface receptor for the viral spike (S) protein to bind to as well as priming of the S protein by cell proteases. More specifically, SARS-CoV-2 utilizes ACE2 as its entry receptor and TMPRSS2 cell protease for S protein priming \[[@CR53]\]. Cross human tissue surveys of ACE2 and TMPRSS2 positive cells found co-expression of these proteins in nasal goblet and ciliated epithelial cells as well as oligodendrocytes \[[@CR54]\]. ACE2/TMPRSS2 co-expression in oligodendrocytes could be one means of CNS infiltration or proliferation.

Cases of acute encephalitis were reported during the SARS-CoV epidemic with virus detected in patient CSF \[[@CR55], [@CR56]\]. Further insight also comes from pathology studies wherein both viral RNA and infectious virus have been detected in brain tissue. A postmortem study examining four individuals with SARS-CoV-related deaths and four control individuals found SARS-CoV antigen and RNA in the cerebrum of the SARS-CoV infected individuals \[[@CR57]\]. Other Human Coronaviruses have previously been found in the brain by autopsy studies: HCoV strains 229E and OC43 were found in 44 out of 90 brain donors as determined by RT-PCR \[[@CR58]\]. Interestingly, the prevalence of OC43 was significantly higher in patients with multiple sclerosis (MS) than in controls. Additionally, another study demonstrated an increase in MCP-1 chemokine mRNA in astrocyte cells lines following HCoV-OC43 infection \[[@CR59]\]. Elevation in MCP-1 has been linked to increased permeability of the blood--brain barrier \[[@CR60]\]. Thus, these results suggest that HCoV infection may exacerbate a predisposition for MS neuropathology and highlight the possibility that coronavirus infection may interact with preexisting or coexisting neuropathology to yield additive or chronic neurologic complications.

Coronaviruses may invade the CNS by either a transneuronal or hematogenous route. One unique feature of SARS-CoV-2, early anosmia, may signify early neuroinvasion through the olfactory bulb as retrograde transport of HCoV from the nasal epithelium to the olfactory nerve and the CNS has been demonstrated in mice models. Three days after intranasal inoculation with HCoV-OC4, transgenic mice were found to have cells containing viral-specific antigens in their olfactory bulbs, but not in the perivascular spaces. By 7 days post-inoculation, there was propagation of the virus throughout the whole brain, coincident with a fatal clinical encephalitis. Like HCoV-OC43, SARS-CoV has also been found in the CNS of mice following experimental nasal inoculation. An approximately eightfold increase in the density of SARS-CoV-positive cells in the CNS was observed over 1--2 weeks after infection, principally clustered in the hippocampus \[[@CR61]\]. SARS-CoV has been clinically associated with cases of encephalitis, ischemic changes in neurons, and viral particles, and genome sequences have been detected in the brain upon human autopsy \[[@CR51]\]. Though SARS-CoV and SARS-CoV-2 share 82% of their genomic identity, SARS-CoV-2 has unique genetic characteristics, notably encoding proteins that may affect both viral replication and pathogenicity \[[@CR62]\]. The implications and significance of these genetic differences are not yet known.

Coronaviruses may alternatively cross into the CNS through a blood--brain barrier compromised by endothelial injury or endotheliitis, inflammatory mediators, transmigration of macrophages carrying the virus, or direct infection of the endothelial cells themselves \[[@CR11], [@CR53], [@CR54], [@CR58]\]. Once established in the CNS, SARS-CoV, the virus responsible for Severe Acute Respiratory Syndrome (SARS), has been shown to be capable of inducing rapid transneuronal spread and death of infected neurons in transgenic mice models expressing human ACE2 receptors \[[@CR63]\]. On the other hand, some mice infected with HCoV-OC43, a human coronavirus that causes the common cold, develop an acute encephalitis with neuronal infection, or may survive acute infection and develop chronic encephalitis characterized by behavioral changes and persistence of the OC43 virus in affected neurons \[[@CR64]\]. Infection of hippocampal and cortical neural cells with HCOV-OC43 in tissue culture has indicated that cell death may occur by apoptosis of both infected and neighboring, non-infected cells \[[@CR64]\]. TNF-⍺, a known trigger for apoptosis, was found to be released by the infected cells and may have contributed to apoptosis in uninfected cells and in infiltration and activation of microglia, a finding consistent with previous studies \[[@CR65]\].

Both SARS-CoV and SARS-CoV-2 enter host cells through ACE2 receptors, but phylogenetic data and atomic-level resolution virus--receptor complex analyses suggest that the novel coronavirus may recognize human ACE2 more efficiently \[[@CR66], [@CR67]\]. In a study that introduced clinical-grade soluble human ACE2 (hrsACE2) and SARS-CoV-2 in engineered human tissue, hrsACE2 was able to effectively scavenge the virus inhibiting its attachment to cells \[[@CR68]\]. ACE2, which is expressed at high levels in various tissues including alveolar type-2 cells, brain endothelial cells, neurons, and glial cells \[[@CR51], [@CR69], [@CR70]\], regulates the renin-angiotensin system by opposing angiotensin-converting-enzyme (ACE) signaling through the production of the vasodilator peptide angiotensin \[[@CR1]--[@CR7], [@CR71]\].

SARS-CoV has been shown to reduce ACE2 levels in the mouse lung without a detectable alteration in ACE expression \[[@CR72]\]. In a study of SARS-CoV transgenic mice that expressed human ACE2 receptors, the transgenic mice showed susceptibility to the virus, more efficient replication of the virus as compared to wild-type mice, more severe pulmonary lesions, detectable viral antigen in the brain, and cerebral vasculitis and hemorrhages \[[@CR73]\]. By downregulating ACE2 expression, SARS-CoV-2 may upset the delicate balance of ACE/ACE2 cerebrovascular control which may result in unopposed ACE signal, excessive vasoconstriction, or disrupted cerebral autoregulation.

Infection with SARS-CoV has previously been shown to be associated with high levels of cytokines, including tumor necrosis factor-alpha (TNFα), interleukin (IL)-1β, IL-6, IL-12, and interferon gamma (INFγ), a phenomenon known as "cytokine storm" \[[@CR1], [@CR74], [@CR75]\], and high levels of these "pro-inflammatory" cytokines have been linked to poor outcomes. SARS-CoV-2 shares such pathogenicity, as COVID-19 severity has now been associated with increased levels of IL-1β, IL-2, IL-6, IL-7, IL-8, IL-10, IL-17, INFγ, INFγ-inducible protein-10, MCP1, G-CSF, TNFα, and macrophage inflammatory protein 1α \[[@CR1], [@CR76]--[@CR81]\]. Elevated ferritin and IL-6, markers of hyper-inflammation, have already been linked to mortality in COVID-19 \[[@CR1], [@CR82]\]. Cytokine storms may contribute to both acute lung injury and neurotoxicity; mice infected with influenza A virus demonstrated significant increases in cytokines IL-6, IL-1β, and TNF-α with vascular hyperpermeability seen in lungs and also the brain within 6 days of inoculation \[[@CR83]\]. The integrity of the blood--brain barrier may be disrupted by cytokine-driven injury and immune-mediated toxicity in the absence of direct viral spread or invasion (Fig. [1](#Fig1){ref-type="fig"}). Observations suggest that acute necrotizing encephalopathy (ANE), as an example, may be mediated by cytokine toxicity \[[@CR84]\]. Cytokines may also be directly neurotoxic, mediate or even inhibit injury to cells of the CNS either alone or acting in synergy \[[@CR85]\]. The ways in which the highly activated cytokine signaling seen in SARS-CoV-2 infection may impact neurologic outcome via alteration of neuroinflammatory pathways are not understood.Fig. 1Infection with the SARS-CoV-2 virus may lead to brain pathology through potential direct and indirect mechanisms. SARS-CoV-2 infection leads to cytokine storms. Recent evidence suggests that interleukin (IL)-1ra, IL-6, Monocyte Chemoattractant Protein (MCP)-3, and serum interferon gammainduced protein (IP)-10 are implicated in the fatal outcomes of COVID-19 infection \[[@CR81], [@CR86]\]. Cytokine storms can damage an intact blood--brain barrier and disrupt normal functioning in the CNS without the virus crossing the blood--brain barrier from the systemic circulation. In addition, COVID-19 has been associated with a pro-thrombotic state, which may lead to occlusion of cerebral vessels and lead to brain injury \[[@CR81]\]. Finally, ACE2, a functional receptor of SARS-CoV-2, may facilitate direct invasion of neurons and cerebrovascular endothelial cells, leading to apoptosis and necrosis of neurons and neighboring cells \[[@CR64]\]. *Original figure created by Nicole J. Katchur*

Conclusion {#Sec4}
==========

The effects of COVID-19 on the nervous system and neurological outcomes after successful treatment have not been well studied. There is an urgent need for clinical and laboratory research to characterize the relationship between SARS-CoV-2 and neurologic injury. In particular, the broad variety of neurologic complications reported in association with COVID-19, such as ischemic or hemorrhagic stroke, encephalopathy, and seizures, suggests direct effects of viral tropism for the CNS, indirect effects through injury to other organ systems, or sporadic synergy between infectious mechanisms and underlying conditions. Mounting evidence suggests that the novel coronavirus is both vasculotropic and neurotropic. To elucidate these pathogenic pathways, larger and more systematic studies will be required, and relevant animal and tissue models must be developed and refined.

Current data on neuropathology associated with COVID-19 are severely limited. This likely reflects under-reporting of neurologic manifestations in the setting of massive coexisting pulmonary injury and sedation, which makes it difficult if not impossible to conduct thorough neurological clinical examinations, particularly in severe cases where such complications may be more common. Furthermore, even when there may be clinical suspicion of neurological involvement, patients with COVID-19 are maintained under strict isolation precautions, and the ability to obtain neuroimaging is limited, further restricting opportunities to observe and study complications and sequelae. However, efforts must be made to circumvent these challenges in order to better characterize SARS-CoV-2 and its neuropathologic potential. These findings will ultimately help clinicians detect neuropathological signs earlier, attempt therapeutic intervention prior to irreversible injury, and identify compelling neurobiological targets for more optimal treatment and prevention of neurologic injury.
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